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Abstract: The intestinal microbiota might contribute to enteropathy associated with 
use of non-steroidal anti-inflammatory drugs (NSAIDs), but there have been few 
human studies of this association. We performed a placebo-controlled study to 
determine whether a delayed release antibiotic formulation (rifaximin-EIR) prevented 
development of intestinal lesions in persons taking daily NSAIDs. Sixty healthy 
volunteers (median age 26 years, 42% female) were given the NSAID diclofenac (75 mg 
twice daily) plus omeprazole (20 mg once daily), and either rifaximin-EIR (400 mg) or 
placebo, twice daily for 14 days. Subjects were assessed by video-capsule endoscopy at 
baseline and after 2 weeks of treatment. The primary endpoint was the proportion of 
subjects developing at least 1 small bowel mucosal break at week 2. Secondary 
endpoints were the change in mean number of mucosal lesions and number of 
subjects with large erosions and/or ulcers after 14 days of exposure. We detected 
mucosal breaks in 20% of subjects given rifaximin and 43% of subjects given placebo 
(P=.05. in the post hoc sensitivity analysis). None of the subjects in the rifaximin group 
developed large lesions, compared with 9 subjects in the placebo group (P<.001). Our 
findings indicate that the intestinal bacteria contribute to development of NSAID-
associated enteropathy in humans. Clinical trial no: EudraCT 2013-000730-36. 
 
KEY WORDS: controlled trial, microbiome, gastrointestinal adverse event, prevention 
 
Short Title: Rifaximin for NSAID-enteropathy 
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Text 
Non-steroidal anti-inflammatory drugs (NSAIDs) are very effective medications, but 
their use is associated with a broad spectrum of adverse reactions involving the liver, 
kidney, cardiovascular (CV) system, skin and gut. Gastrointestinal (GI) adverse effects 
are the most common and cover a wide clinical spectrum, ranging from dyspepsia, 
heartburn and abdominal discomfort to more serious events, such as peptic ulcer with 
life-threatening ulcer complications of bleeding and perforation [1].  
Over the past decade, there has been a progressive change in the overall pattern of GI 
events leading to hospitalization, with a clear decreasing trend in upper GI events and 
a slight, but significant, increase in lower GI events [2].  Indeed, available studies [3, 4] 
have shown that about 75% of NSAID users display intestinal mucosal injury, ranging 
from denuded areas (seen mainly in the proximal small bowel) to the so-called 
mucosal breaks (erosions and ulcers), observed in its distal part. While the incidence of 
upper GI injury can be reduced by proton pump inhibitors (PPIs), this is not the case for 
NSAID-associated intestinal lesions, which may actually be aggravated by acid 
suppression [5]. 
The pathogenesis of small intestinal damage is complex and still not completely 
understood. Several lines of experimental evidence implicate commensal 
enterobacteria in the pathogenesis of NSAID-enteropathy and suggest that luminal 
bacterial may represent a potential target for prevention/or treatment [6]. In this 
context, the efficacy of a delayed release formulation of rifaximin, a poorly absorbed 
antibiotic [7], in the prevention of NSAID-associated lesions was evaluated in man, by 
means of video-capsule endoscopy. 
Sixty healthy volunteers (median age 26 years, 42% female) were randomized to 
receive diclofenac SR 75 mg BID plus omeprazole 20 mg OD and either rifaximin-EIR 
400 mg or rifaximin-EIR matching placebo BID for 14 days (Figure 1). The primary 
endpoint was the proportion of subjects developing at least one small bowel mucosal 
break at final VCE. Secondary endpoints were the change at VCE in the mean number 
of mucosal lesions and the number of subjects with large erosions and/or ulcers at the 
end of treatment (see Supplementary Material and Supplementary Table). 
Six patients in the rifaximin group and 13 patients in the placebo group (12 of per 
protocol set) developed at least one mucosal lesion in the small bowel (primary end-
point), which gives an odds ratio (OR) of 0.33 [95% CI 0.10, 1.03] and 0.35 [95% CI 0.11, 
1.12] in the modified full analysis (mFA) and PP sets, respectively, for subjects in the 
rifaximin group to develop at least one mucosal lesion in the small bowel at logistic 
regression analysis.  
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The efficacy on primary end-point was not significant. However, when post-hoc 
sensitivity analysis, using age as covariate, was performed, the difference between 
rifaximin and placebo group became significant (Table 1). The average mucosal score 
(mFA set) at the end of the treatment was 0.87±0.13 versus 1.83±0.28 for rifaximin 
and placebo, respectively (p=0.021). 
Both secondary end-points were successfully reached in the study (Table 1). Subjects 
in the placebo group developed a higher number of mucosal lesions compared to 
those in the rifaximin group (1.2±2.3 vs. 0.3±0.7 in the mFA set). Negative binomial 
regression analysis proved a protective effect of rifaximin on mean changes from 
baseline in total number of lesions (treatment effect point estimate [PE] -1.41 [95% CI -
2.49, -0.34]; p-value=0.010). A similar result was detected for the change from baseline 
in the number of lesions without hemorrhage (PE -1.44 [95% CI -2.53, -0.35; p-
value=0.009).  
Both treatments were well tolerated and no serious adverse events were recorded. 
This is the first randomized, controlled trial, investigating the effect of an antibiotic on 
NSAID-induced intestinal mucosal injury in human beings. This study shows that fewer 
rifaximin-treated volunteers developed small bowel lesions compared to placebo-
treated subjects. The antibiotic also reduced the mean number of lesions and 
appeared to abolish the larger lesions, with a tolerability profile, overlapping that of 
placebo. Although short-term studies, such as this one, and mucosal breaks may not 
have straightforward clinical implications [8], the results of this proof-of-concept study 
strongly suggest the role of enteric bacteria in the pathogenesis of NSAID-enteropathy.  
and call for a prospective trial in patients on long-term NSAID therapy. 
The entero-protective effect of rifaximin most likely depends on its broad spectrum of 
antibacterial activity [7]. Experimental studies [9-11] not only show that this antibiotic 
reduces the total bacterial load, but also modulates bacterial community composition, 
an effect associated with a reduction of intestinal inflammation [10, 11] and 
improvement of gut barrier function [10].  
Recent evidence points out that – besides non-antimicrobial activities – rifaximin may 
also displays “eubiotic” properties. Indeed, in patients with inflammatory conditions 
(like inflammatory bowel disease, colonic diverticular disease or hepatic 
encephalopathy), the drug -  while not altering the overall structure of human colonic 
microbiota - increased the relative abundance of Bifidobacteria and Lactobacilli [12, 
13].  
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NSAID-enteropathy is associated with significant GI complications [14, 15], but there 
are no proven strategies for the prevention or healing of this subtle clinical condition. 
However, there is now good evidence that intestinal bacteria play a pathogenic role in 
NSAID-enteropathy in man.  Treatments aiming at correcting the shift of intestinal 
microbiota towards pro-inflammatory Gram-negative bacteria [6] are therefore 
potential avenues to explore in the prevention and treatment of NSAID-enteropathy. 
After almost 40 years, with the advancement of knowledge on the pathogenic role of 
gut microbiota in NSAID-enteropathy [6], the time seems now ripe to study in well-
designed, large, randomized, clinical trials microbiota-directed interventions to protect 
the small bowel from NSAID injury and to allow safer anti-inflammatory therapy. 
 
 
 
 
 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT 2
nd
 Revised Version 
December 6, 2016 
 
 7
References 
 
1. Scarpignato C, et al. BMC Med 2015; 13: 55. 
2. Lanas A, et al. Am J Gastroenterol 2009; 104: 1633-41. 
3. Graham DY, et al. Clin Gastroenterol Hepatol 2005; 3: 55-9. 
4. Maiden L, et al. Gastroenterology 2005; 128: 1172-8. 
5. Washio E, et al. Clin Gastroenterol Hepatol 2016; 14: 809-815. 
6. Scarpignato C. Gut 2008; 57: 145-8. 
7. Scarpignato C, et al. Chemotherapy 2005; 51 (Suppl 1): 36-66. 
8. Bar-Meir S. Aliment Pharmacol Ther 2006; 24 (Suppl 3): 19-21. 
9. Kim MS, et al. Dig Dis Sci 2013; 58: 1676-82. 
10. Xu D, et al. Gastroenterology 2014; 146: 484-96.e4. 
11. Fornai M, et al. Pharmacol Res 2016; 104: 186-96. 
12. Maccaferri S, et al. J Antimicrob Chemother 2010; 65: 2556-65. 
13. Ponziani FR, et al. Dig Dis 2016; 34: 269-78. 
14. Bjarnason I, et al. Lancet 1987; 2: 711-714 
15. Chan FK, et al. Lancet 2010; 376: 173-179 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Table 1 - Primary and Secondary Endpoints of the Study  
 
Primary End-point Rifaximin Placebo p value 
No of subjects developing at 
least  one  mucosal  lesion 
6/30 (20%) 13/30 (43%) 0.0566
1
 
Sensitivity Analysis (treatment and sex as fixed effect and age as covariate) 0.0490 
Secondary End-points  
Change in the mean number 
(± SEM) of mucosal lesions  
0.3±0.7 1.2±2.3 0.0103
2
 
Number of subjects with large 
erosions and/or ulcers at the end 
of treatment 
0 9 0.001
3
 
1
Logistic Regression Analysis       
2
Negative Binomial Regression Analysis        
3
Chi-
square Test 
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Subjects and Methods 
This double-blind, randomized, placebo-controlled, phase IIa trial was conducted 
according to the CONSORT guidelines [16] at the Department of Clinical Pharmacology 
at the General Hospital of Vienna, Austria. The study protocol was approved by the 
internal review board of the Medical University of Vienna (EK 1244/2013) and the 
national competent authority (Ref N. 718031). The study was registered at EudraCT 
(2013-000730-36). 
The trial was performed according to the International Conference on Harmonization 
of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 
guidelines for Good Clinical Practice (GCP) [17] and the Declaration of Helsinki (1996 
version, amended October 2000) [18]. 
 
Study Subjects and Baseline Evaluations 
Healthy male and female volunteers (18-64 years) gave their availability and 
willingness to participate in the study. Sixty subjects met all the inclusion criteria, i.e. 
unremarkable physical examination and medical history, normal vital signs, and all 
laboratory test values (including hematology, blood chemistry, virology, urinalysis and 
screened for drug of abuse) within the reference ranges. Female subjects with child 
bearing potential were required to have negative urine pregnancy test. Exclusion 
criteria included any serious neurologic, psychiatric, cardiovascular, respiratory, 
gastrointestinal, renal or musculoskeletal disease, drug misuse including alcohol, 
pregnancy and age outside the 18-64 year range. Subjects having used steroids, non-
steroidal anti-inflammatory drugs, biphosphonates, sulphasalazine, biological drugs, 
treatments targeting gut microbiota (antibiotics, prebiotics or probiotics) as well as 
gastrointestinal prokinetic drugs within the previous 30 days were also excluded. The 
use of these drugs, even occasionally, was prohibited during the study. 
All participants were admitted to the Investigational Unit. After overnight stay at the 
department with appropriate preparation (see below) eligible subjects underwent VCE 
of the small bowel (baseline VCE). To be included in the study, video capsule 
endoscopy should have shown no abnormality, but a maximum of one mucosal break, 
(erosion or ulcer) in the small bowel was allowed.  
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Study treatment 
After re-assessment of inclusion/exclusion criteria subjects were randomized 
according to a computer-generated list on a 1:1 basis to receive diclofenac SR 75 mg 
BID (Voltaren, Novartis Farma S.p.A., Italy) plus omeprazole 20 mg OD (Losec, 
AstraZeneca AB, Sweden) plus either rifaximin-EIR 400 mg (Alfa Wasserman S.p.A., 
Italy) or rifaximin-EIR matching placebo BID (Alfa Wasserman S.p.A., Italy) for a total of 
14 days. Amongst different NSAIDs, diclofenac was selected because its administration 
is associated with a definite risk small intestinal injury [19] and because it has been 
used in almost all the video capsule studies, carried out on the topic with VCE [for 
review see 20]. In a previous study [4], we found that its slow-release formulation 
(combined with omeprazole) was associated – after 14 days – with intestinal mucosal 
lesions in 68% of healthy subjects. 
Drug intake was performed and witnessed at the study site at 8 A.M. and 8 P.M. (+/- 1 
hour). Within 36 hours after the last study drug intake, the subjects underwent a 
second VCE assessment (final VCE), vital signs check, physical examination and safety 
laboratory tests (hematology, blood chemistry and urinalysis). In case of study 
withdrawal, an early termination visit including final VCE was performed. All patients 
were followed up using a telephone interview one week after the final VCE visit to 
assure capsule excretion.   
 
Video Capsule Endoscopy 
Baseline and post-treatment VCE were performed on an inpatient basis at the study 
site. On the day prior to VCE subjects were allowed to eat solid food until 1:00 p.m. 
and to drink clear liquids until 10:00 p.m. In the evening they received two liters of a 
polyethylene glycol (PEG) washout solution (Klean-Prep, Norgine, Germany), according 
to the current guidelines [21] and on-site protocol [22]. The next morning VCE was 
performed after attachment of the sensor belt and data recorder. Before swallowing 
the capsule (PillCam SB2, Given Imaging, Yokneam, Israel) all subjects received 70 mg 
of simethicone (Sab-Simplex, Pfizer, Austria) to avoid visual interference by intestinal 
air bubbles [23, 24]. Subjects were allowed to drink clear liquids two hours after 
capsule intake and to eat a light meal two hours later. Sensor belt and data recorder 
were detached after a total capsule operation time of 8 hours. All capsule videos were 
pre-analyzed on site by a gastrointestinal endoscopist (WD) with experience in VCE, 
who had no knowledge of the treatment regimen. VCE results were re-evaluated 
blindly by a panel of three independent VCE-experts (IB, AL, CS). In case of 
disagreement between initial evaluation and re-assessment, consensus was achieved 
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on the final diagnosis between WD and the three VCE-experts. Patient’s data remained 
blinded until final consensus was achieved. All findings were classified following the 
“five-point scoring system for endoscopic lesions with capsule endoscopy” 
(Supplementary Table 1) [3]. 
 
Study endpoints 
 
The primary endpoint of the study was the proportion of subjects developing at least 
one mucosal break, defined as erosion or ulcer, in the small bowel at final VCE. 
Secondary endpoints were the change from baseline to final VCE in the number of 
mucosal breaks, those with and those without hemorrhage, as well as factors 
reflecting safety and tolerability of the study treatment like the distribution of 
treatment-emergent adverse events (TEAEs, defined as all adverse events occurring or 
worsening after the first dose of the study medication), overall adverse events (AEs) or 
a change in clinical laboratory parameters and vital signs.  
 
Statistical Analyses 
Based on an estimated rate of mucosal lesions of 58% in the control group, a sample 
size of 60 subjects (30 subjects per group) was calculated to detect a reduction of 
approximately 33% in the primary endpoint for subjects in the active group, 
considering a one-sided significance level of 0.05, a power of 80% and a 10% dropout 
rate. Descriptive statistics were used to report baseline characteristics and final 
results. Statistical analyses were performed for the following datasets: modified Full 
Analysis set (mFA), consisting of all randomized subjects who received at least one 
dose of study medication and who successfully completed the final VCE; per Protocol 
set (PP), consisting of all randomized subjects included in the mFA without any major 
protocol deviation; safety set (SA), consisting of all randomized subjects who received 
at least one dose of study medication. Logistic regression analysis and McNemard Chi-
Square test were used for comparison of the primary endpoint between groups. A 
negative binomial model with the change from baseline as dependent variable and 
treatment as fixed effect was used to compare the secondary efficacy endpoints 
between groups. Safety parameters were only reported descriptively. SAS version 9.1.3 
Service Pack 4 for Windows
®
 was used for all statistical analyses in the context of this 
study. As customary, codes were broken only after the statistical analysis of primary 
and secondary end-points. 
All authors had access to the study data, checked the statistical analyses and reviewed 
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and approved the final manuscript. 
 
 
 
 
 
 
Supplementary Table 1 - Five-Point Scoring System for Endoscopic Lesions 
With Capsule Endoscopy 
 
Category Score 
Normal 0 
Petechiae/red spot (demarcated, usually circular, area of 
crimson mucosa with preservation of villi) 
1 
Small number of erosions (1-4 erosions) 2 
High number of erosion (>4 erosions) 3 
Mucosal breaks (large erosion and/or ulcer) 4 
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